Novel genetic markers, such as TGFB1 rs4803455 and PLCB1 rs170549, may serve as tools that clinicians can utilize to assess a patient’s risk of CNI-associated renal dysfunction following heart transplantation, thereby improving clinical care and advancing precision medicine in this population. This evidence concerns the gene TGFB1 and Abnormal renal physiology.